3 Under-the-Radar Defense Stocks With Record Backlogs

The Pentagon is seeking $1.1 trillion in FY2027 discretionary spending, including a 188% increase in missile-procurement funding, supporting demand for defense suppliers beyond prime contractors. ATI has a record $4.4 billion backlog, expects to deliver 70% within 12 months, and targets mid-20% AA&S margins; Astronics posted 27% Q2 revenue growth and a record $780 million backlog but carries a 1.57 debt-to-equity ratio. Ducommun delivered record Q2 revenue of $224.5 million, up 12% year over year, with missile revenue up 68% and gross margin at 28%, but reiterated guidance for only low-single-digit growth in Q3 and Q4 amid commercial destocking and pulled-forward aerospace production.

Analysis

The differentiated exposure is upstream: ATI monetizes scarcity before program-level economics reach LMT or RTX. Qualified titanium/nickel-based alloys and specialty metals have long certification cycles, making substitution difficult and allowing ATI to preserve price even if prime contractors face fixed-price development losses or labor inflation. The near-term issue is valuation: at roughly 62x trailing earnings, the stock needs backlog conversion to translate into visible EPS and free-cash-flow acceleration over the next 2-3 quarters; a broad defense-budget narrative alone is unlikely to sustain further multiple expansion.

DCO has the clearest estimate-risk asymmetry. Its missile mix can conceal weakness in commercial aerospace, radar, naval, and space programs; if commercial inventory normalization lasts another quarter, consensus revenue and margin assumptions are likely too high despite the order book. The key distinction is that backlog is not fungible: delivery schedules, customer-funded inventory, and program mix determine cash conversion. With the next earnings report still weeks away, reduced guidance risk can produce a persistent de-rating rather than a one-day technical bounce.

ATRO is the highest-beta expression of aerospace production rates, not a clean missile-spending proxy. Leverage amplifies equity upside if OEM production and bookings remain strong, but also makes a modest working-capital build or rate slowdown disproportionately damaging to equity value. The contrarian read is that the market may be overpaying for small-cap "defense" exposure: aerospace suppliers with commercial exposure can lag pure defense primes if appropriations are delayed or commercial OEM supply-chain constraints re-emerge.

Budget requests are not appropriations. Over the next 1-3 months, continuing-resolution risk could delay new starts and defer supplier releases even if the multi-year demand signal remains favorable. Over 6-18 months, sustained missile replenishment should favor constrained component/material suppliers, but only where management can demonstrate margin conversion and not merely backlog growth.

Key Decisions for Investors

• Initiate a measured long ATI / short DCO pair over a 3-6 month horizon. ATI offers scarcity-driven pricing and faster backlog conversion, while DCO faces a near-term growth-air-pocket risk; target 15-20% relative outperformance. Exit if ATI's next report shows AA&S margin below the mid-20% range or if DCO raises second-half growth guidance materially.
• Do not chase ATRO after its sharp run. Set an alert for a post-results entry only if bookings remain above revenue, net leverage declines, and management confirms aerospace demand is translating to cash flow; absent those data, downside from a revenue miss is likely larger than the incremental upside from the defense narrative.
• For broad defense exposure, prefer LMT or RTX over ATRO as the lower-volatility vehicle until appropriations timing is clearer. Add only on evidence of funded missile-program awards rather than headline budget requests; a continuing resolution extending beyond the fiscal-year start would be a near-term negative catalyst for smaller suppliers.
• Maintain a tactical short or underweight in DCO into the next earnings release if the stock fails to reclaim its 50-day average and analyst estimates remain unchanged. Cover on evidence that commercial destocking has ended, missile strength broadens into other platform categories, or management lifts near-term revenue guidance.